Bellete Ambaw 4

What Happened
Bellete Ambaw, President and COO of CG Oncology (CGON), was awarded derivative securities representing 107,508 shares on April 15, 2026. The award was reported at an acquisition price of $0.00 (no cash paid). The filing indicates the award vests monthly (1/48th) beginning April 15, 2026, subject to her continued service.

Key Details

• Transaction date: 2026-04-15; reported on Form 4 filed 2026-04-16 (timely filing).
• Transaction type: Grant / Award of derivative securities (code A) at $0.00 per share (no cash exchanged).
• Vesting: 1/48th of the shares vest monthly following April 15, 2026 (4-year monthly vesting), subject to continuous service (Footnote F1).
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or sale proceeds noted in this filing.

Context
This was an equity award as part of compensation rather than an open-market purchase or sale. Because the award vests over time, it does not represent immediate sellable stock and is contingent on continued service. Awards like this are common executive compensation and do not, by themselves, indicate an insider buying or selling in the market.